EP3509636A4 - Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns - Google Patents

Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns Download PDF

Info

Publication number
EP3509636A4
EP3509636A4 EP17848290.7A EP17848290A EP3509636A4 EP 3509636 A4 EP3509636 A4 EP 3509636A4 EP 17848290 A EP17848290 A EP 17848290A EP 3509636 A4 EP3509636 A4 EP 3509636A4
Authority
EP
European Patent Office
Prior art keywords
cns
injury
disease
activity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17848290.7A
Other languages
English (en)
French (fr)
Other versions
EP3509636A1 (de
Inventor
Michal Eisenbach-Schwartz
Kuti BARUCH
Neta ROSENZWEIG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/261,945 external-priority patent/US10519237B2/en
Priority claimed from PCT/IB2016/001433 external-priority patent/WO2017042633A2/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to EP23184844.1A priority Critical patent/EP4269439A3/de
Publication of EP3509636A1 publication Critical patent/EP3509636A1/de
Publication of EP3509636A4 publication Critical patent/EP3509636A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manipulator (AREA)
EP17848290.7A 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns Withdrawn EP3509636A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23184844.1A EP4269439A3 (de) 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/261,945 US10519237B2 (en) 2014-03-12 2016-09-10 Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
PCT/IB2016/001433 WO2017042633A2 (en) 2015-09-10 2016-09-10 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
PCT/IL2017/051011 WO2018047178A1 (en) 2016-09-10 2017-09-08 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23184844.1A Division EP4269439A3 (de) 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns

Publications (2)

Publication Number Publication Date
EP3509636A1 EP3509636A1 (de) 2019-07-17
EP3509636A4 true EP3509636A4 (de) 2020-12-16

Family

ID=61561788

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23184844.1A Pending EP4269439A3 (de) 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns
EP17848290.7A Withdrawn EP3509636A4 (de) 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23184844.1A Pending EP4269439A3 (de) 2016-09-10 2017-09-08 Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns

Country Status (9)

Country Link
EP (2) EP4269439A3 (de)
JP (2) JP7074662B2 (de)
KR (2) KR20190050931A (de)
CN (2) CN116492457A (de)
AU (2) AU2017322656B2 (de)
CA (1) CA2997578A1 (de)
IL (4) IL300982B1 (de)
MX (1) MX2018003028A (de)
WO (1) WO2018047178A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN117736325A (zh) 2016-08-09 2024-03-22 科马布有限公司 分离抗体及其应用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
WO2019227090A1 (en) * 2018-05-25 2019-11-28 Memorial Sloan Kettering Cancer Center Diagnosis and treatment of immunotherapy-induced neurotoxicity
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
CN111956799A (zh) * 2020-09-18 2020-11-20 生物抗素公司 抗pd-1抗体和/或pd-l1抗体在制备治疗帕金森病药物中的应用
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040301A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106586A1 (en) * 2003-06-13 2005-05-19 Mount Sinai Hospital Detection of neurodegenerative diseases
CN1838950A (zh) * 2003-06-23 2006-09-27 神经化学（国际）有限公司 治疗蛋白质聚集疾病的方法
ES2437491T3 (es) * 2003-10-10 2014-01-10 Alchemia Oncology Pty Limited Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
CA2791930A1 (en) * 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
EP3013355B1 (de) * 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 zur verwendung in der behandlung von alzheimer-krankheit und verwandten erkrankungen
US9394365B1 (en) * 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR20230097209A (ko) * 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040301A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. D. HUEY ET AL: "A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia", NEUROLOGY, vol. 66, no. 1, 9 January 2006 (2006-01-09), pages 17 - 22, XP055092755, ISSN: 0028-3878, DOI: 10.1212/01.wnl.0000191304.55196.4d *
JOSEPHS ET AL: "Argyrophilic grains: A distinct disease or an additive pathology?", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 29, no. 4, 3 March 2008 (2008-03-03), pages 566 - 573, XP022509460, ISSN: 0197-4580, DOI: 10.1016/J.NEUROBIOLAGING.2006.10.032 *

Also Published As

Publication number Publication date
KR20240064742A (ko) 2024-05-13
EP4269439A2 (de) 2023-11-01
EP4269439A3 (de) 2024-01-17
JP7451596B2 (ja) 2024-03-18
WO2018047178A1 (en) 2018-03-15
KR20190050931A (ko) 2019-05-14
CN108348607A (zh) 2018-07-31
CN116492457A (zh) 2023-07-28
JP2019530635A (ja) 2019-10-24
AU2017322656A1 (en) 2018-04-19
MX2018003028A (es) 2018-05-28
IL300982B1 (en) 2024-04-01
IL291784A (en) 2022-06-01
AU2017322656B2 (en) 2024-02-29
IL311841A (en) 2024-05-01
JP2022106983A (ja) 2022-07-20
IL291784B1 (en) 2023-05-01
CA2997578A1 (en) 2018-03-10
AU2024203073A1 (en) 2024-05-30
IL300982A (en) 2023-04-01
IL257885A (en) 2018-06-28
JP7074662B2 (ja) 2022-05-24
EP3509636A1 (de) 2019-07-17
IL291784B2 (en) 2023-09-01
CN108348607B (zh) 2023-06-23
IL257885B (en) 2022-05-01

Similar Documents

Publication Publication Date Title
IL256792A (en) Reduction of the level of regulatory t cells or their activity for the treatment of diseases and damages in the central nervous system
EP3509636A4 (de) Reduzierung von systemischen regulatorischen t-zellenkonzentrationen oder -aktivitäten zur behandlung von erkrankungen oder verletzungen des zns
EP3308793A4 (de) Therapeutikum für hautwunde oder raue haut
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL266047A (en) Methods and preparations for the treatment of Fabry disease
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
SG10201912134TA (en) Methods and composition for the prediction of the activity of enzastaurin
EP3463324A4 (de) Levocetirizin und montelukast bei der behandlung von strahleninduzierten erkrankungen
PT3481819T (pt) Compostos e a sua utilização para reduzir os níveis de ácido úrico
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
HK1257236A1 (zh) 預防和治療高脂血症的藥物及其用途
EP3253766A4 (de) Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
HK1257585A1 (zh) 預防和治療皮膚纖維化的藥物及其用途
AU2017267955B2 (en) Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
IL272121A (en) Preparation and methods for the treatment of myopia
PL3389653T3 (pl) 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych
EP3374354A4 (de) Benzofuranderivate zur behandlung des zentralen nervensystems (zns) und anderen erkrankungen
EP3697387A4 (de) Kombination aus as1411 und sapc-dops zur behandlung von glioblastoma multiforme
EP3308794A4 (de) Therapeutikum für hautwunde oder raue haut
EP3156054A4 (de) Medikament zur vorbeugung und/oder behandlung von stressbedingten erkrankungen
EP3344337A4 (de) Verfahren und zusammensetzungen zur behandlung von zytoplasmatischen glycogenspeichererkrankungen
IL266726A (en) Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
EP3400025A4 (de) Verwendung von guajakol zur vorbeugung und behandlung von glycogenspeicherkrankheiten
EP3302684A4 (de) Verfahren und vorrichtungen zur behandlung der hornhaut

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/00 20060101ALI20200714BHEP

Ipc: A61P 25/28 20060101ALI20200714BHEP

Ipc: A61K 39/395 20060101AFI20200714BHEP

Ipc: C07K 16/28 20060101ALI20200714BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20201117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20201111BHEP

Ipc: A61P 27/00 20060101ALI20201111BHEP

Ipc: A61K 39/395 20060101AFI20201111BHEP

Ipc: C07K 16/28 20060101ALI20201111BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230712